NCT00444782已完成2 期
"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pharmexa A/S
- 入组人数
- 41
- 试验地点
- 6
- 主要终点
- Response rate (Partial and Complete Response) according to modified RECIST.
研究概览
简要总结
The purpose of this study is to investigate the efficacy of GV1001 in locally advanced or metastatic HCC. Also the safety of GV1001 and immunogenicity will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hepatocellular carcinoma diagnosis fulfilling one of the following criteria (as per the American Association for the Study of Liver Diseases [AASLD] guidelines, see Appendix 5):
- •Nodule in a cirrhotic or non-cirrhotic liver with a biopsy showing HCC;
- •Nodule in cirrhotic liver where no biopsy is performed:
- •Nodules between 1-2 cm in a cirrhotic liver with a typical coincidal vascular pattern of HCC (i.e. hypervascular with washout in the portal/venous phase) in two dynamic studies: either CT scan, contrast ultrasound or MRI with contrast.
- •Nodule larger than 2 cm in a cirrhotic liver with a typical vascular pattern of HCC on a dynamic imaging technique.
- •Please note: HCC in a non-cirrhotic liver can only be diagnosed with a biopsy showing HCC.
- •Measurable disease according to modified RECIST (see Appendix 7).
- •At least one treatment-naïve target lesion (treatment-naïve being defined as not having been treated with local therapy, such as surgery, radiation therapy, hepatic arterial embolisation, chemoembolisation, radio-frequency ablation or cryo-ablation).
- •Barcelona Clinic Liver Cancer (BCLC) stage A, B or C (see Appendix 6) (Stage D is excluded).
- •Child-Pugh stage A (see Appendix 8).
- •Male or female aged 18 years or older.
- •Adequate haematological parameters, as demonstrated by:
- •Haemoglobin greater than or equal to 9.0 g/dL (SI units: 5.6 mmol/L);
- •WBC greater than or equal to 3.0 x 109/L;
- •Platelets greater than or equal to 75 x 109/L.
- •ALT and AST ≤ 5 times the upper limit of normal.
- •Bilirubin < 2 mg/dL.
- •Serum creatinine smaller than or equal to 1.5 mg/dL (SI units: 132 µmol/L).
- •Performance status ECOG 0 or
- •Minimum life expectancy of 3 months at screening.
- •Written informed consent given prior to any study specific procedures.
排除标准
- •HCC amenable to curative treatment or transplantation.
- •History of other malignancies in the last 5 years (10 years in the case of breast cancer), except for adequately treated non-melanoma skin cancers (Basal Cell Carcinoma, Squamous Cell Carcinoma) and carcinoma in situ of the cervix.
- •Known history of or co-existing autoimmune disease.
- •Known Central Nervous System (CNS) metastases.
- •Known history of human immunodeficiency virus (HIV).
- •Any medical condition that, in the opinion of the Investigator, may compromise the compliance of the patient to receive study treatment and follow study procedures.
- •Treatment with any other IMP within 4 weeks prior to cyclophosphamide administration at Day -
- •Known sensitivity to any components of cyclophosphamide, GV1001 or GM-CSF.
- •Concomitant treatment with the following within 4 weeks of pre-treatment with cyclophosphamide:
- •Anti-tumour treatment (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, cytokines, interferons, protease inhibitors, and gene therapy) and vaccines.
- •Chronic corticosteroids (inhaled and topical steroids are permitted including low dose steroids at non-immunosuppressive doses e.g. 15 mg prednisolone daily for up to 7 days).
- •Herbal medicine either containing hypericum perforacum (e.g., St Johns Wort) or claiming to have anti-tumour effects (e.g., Iscador).
- •Pregnancy or lactation.
- •Women of childbearing potential not using reliable and adequate contraceptive methods, defined as the use of oral, implanted, injectable, mechanical or barrier products for the prevention of pregnancy; or women who are practising abstinence; or where the partner is sterile, for example a vasectomy.
- •Unable for any other reason to comply with the protocol (treatment or assessments).
结局指标
主要结局
Response rate (Partial and Complete Response) according to modified RECIST.
次要结局
- Time to Progression (TTP)
- Time to Symptomatic Progression (TTSP)
- Progression Free Survival (PFS)
- Immune Response
研究者
研究点 (6)
Loading locations...
相似试验
终止
1 期
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsLocally Advanced Solid TumorNCT05275478Tango Therapeutics, Inc.110
招募中
1 期
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsLocally Advanced Solid TumorNCT05732831Tango Therapeutics, Inc.225
进行中（未招募）
1 期
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid TumorsSolid TumorNCT03364400Vigeo Therapeutics, Inc.116
招募中
2 期
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLAcute Myeloid Leukemia (AML)NCT02781883Bio-Path Holdings, Inc.108
已完成
2 期
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar DysplasiaVulvar Intraepithelial Neoplasia (VIN)VIN2VIN3Pre-cancerous Lesions of the VulvaHuman Papillomavirus (HPV)NCT03180684Inovio Pharmaceuticals33